Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

The Oncologist, Vol. 13, No. 3, 299-305, March 2008; doi:10.1634/theoncologist.2007-0139
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loeb, S.
Right arrow Articles by Catalona, W. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Loeb, S.
Right arrow Articles by Catalona, W. J.

Genitourinary Cancer

What to Do with an Abnormal PSA Test

Stacy Loeba, William J. Catalonab

aDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; bThe Northwestern Feinberg School of Medicine, Chicago, Illinois, USA

Key Words. Prostate cancer • Prostate-specific antigen • PSA • Screening • Detection • Prognosis

Correspondence: William J. Catalona, M.D., 675 N. Saint Clair Street, Suite 20-150, Chicago, Illinois 60611, USA. Telephone: 312-695-4471; Fax: 312-695-1482; e-mail: wcatalona{at}nmff.org

Disclosure: W.C. has received PSA kits at cost and participated in scientific studies with Beckman Coulter (Fullerton, CA). No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

For more than a decade, prostate-specific antigen (PSA) has been used for prostate cancer screening. Over the years, this screening has been continually refined, including investigation into the use of lower total PSA thresholds, PSA isoforms, and PSA kinetics. This review describes the evolution of prostate cancer screening and provides clinical insights into the informed use of PSA and its adjunctive measurements.




This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
J. McLarty, R. L.H. Bigelow, M. Smith, D. Elmajian, M. Ankem, and J. A. Cardelli
Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro
Cancer Prevention Research, July 1, 2009; 2(7): 673 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
M. S. Lucia, A. K. Darke, P. J. Goodman, F. G. La Rosa, H. L. Parnes, L. G. Ford, C. A. Coltman Jr., and I. M. Thompson
Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention
Cancer Prevention Research, August 1, 2008; 1(3): 167 - 173.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Barry
Commentary: How Serious Is Getting a Diagnosis of Prostate Cancer?
Oncologist, March 1, 2008; 13(3): 306 - 308.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.
Advertisement